ALNY
Alnylam Pharmaceuticals
Pharmaceutical Preparations · Health Care
$159.89+1.20%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Mixed profile
Revenue CAGR, 3Y lifts this profile the most.
As of 2025-12-31. Latest quarter ended 2026-09-30. v1 methodology, subject to change.
The profile score is 21 points higher since last quarter. Profits is 42 points higher. Price is 28 points higher.
Sector rank 17 of 46
In plain English
- Alnylam Pharmaceuticals operates in Pharmaceutical Preparations.
- Latest-year revenue was 3.7 billion.
- The profile score is 56, a Mixed profile. Growth is the strongest listed input.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2025-12-31. Latest quarter ended 2026-09-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
P/E vs own history
Now 68.6 times, 5-year median 355.1 times.
Line is the quarterly multiple. The band is the 25th to 75th percentile of that history. The dashed line is the median.
Earnings
Actual earnings per share from EDGAR filings. Historical estimates are not used.
Actual from EDGAR
Data confidence
The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.
SEC EDGAR companyfacts, fetched 2026-11-01.